S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA. (23rd June 2022)

• Record Type: Journal Article
• Authors: Wang, M. L.; Jurczak, W.; Jerkeman, M.; Trotman, J.; Zinani, P. L.; Belada, D.; Boccomini, C.; Flinn, I. W.; Giri, P.; Goy, A.; Hamlin, P. A.; Hermine, O.; Hernández-Rivas, J.-Á.; Hong, X.; Kim, S. J.; Lewis, D.; Mishima, Y.; Özcan, M.; Perini, G. F.; Pocock, C.; Song, Y.; Spurgeon, S. E.; Storring, J. M.; Walewski, J.; Zhu, J.; Qin, R.; Henninger, T.; Deshpande, S.; Howes, A.; Le Gouill, S.; Dreyling, M.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 110
• Page End: 111
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843728.37710.5f
• Languages: English
• ISSNs: 2572-9241